OASIS DERMATOLOGY GROUP

Ph: (956) 971 - 0404
www.oasisderm.com

Calcipotriene

Calcipotriene, also known as calcipotriol, is a synthetic analog of calcitriol, the active form of vitamin D. Initially marketed in the United States under the brand name Dovonex, calcipotriene has primarily been used for the management of psoriasis. However, it has demonstrated potential in treating various other dermatologic conditions, offering additional off-label uses. Calcipotriene regulates keratinocyte proliferation and differentiation, making it a valuable therapeutic option in managing skin disorders characterized by abnormal cell growth.

Mechanism of Action

The discovery of calcipotriene's efficacy in treating psoriasis emerged during research on the effects of vitamin D analogs in osteoporosis. It was noted that patients with psoriatic lesions showed a reduction in the number of lesions when treated with vitamin D analogs, leading to further investigation into calcipotriene’s role in psoriasis management.

Calcipotriene is believed to exert its therapeutic effects by regulating the immune response and keratinocyte differentiation. While the exact mechanism remains unclear, it is known to inhibit keratinocyte proliferation and accelerate the maturation of skin cells without causing cytotoxicity. Calcipotriene regulates the expression of immune markers associated with psoriatic inflammation, which helps to normalize the skin's immune function, reducing inflammatory cytokine activity.

Studies have shown that calcipotriene significantly reduces psoriatic plaques. In an 8-week study where patients applied calcipotriene ointment twice daily, approximately 70% experienced marked improvement, with complete resolution in 11% of patients. The use of calcipotriene cream twice daily also demonstrated positive results, with 50% improvement and 4% resolution. Notably, once-daily dosing was found to be equally effective as twice-daily application, suggesting that frequency of use does not necessarily correlate with enhanced efficacy.

Approved Uses

Calcipotriene is FDA-approved for the treatment of mild to moderate plaque psoriasis in adults over the age of 18. It is commonly prescribed as an ointment or cream for the management of psoriatic lesions on the skin. Additionally, calcipotriene topical solution is approved for chronic scalp psoriasis. Beyond these approved indications, calcipotriene has shown potential in the off-label treatment of several other dermatologic conditions, including: Morphea (Localized scleroderma), Porokeratosis, Vitiligo, Lichen planus, Lichen nitidus, Nail psoriasis, and Pityriasis rubra pilaris.

These off-label uses arise from its immunomodulatory properties, which help manage inflammatory and proliferative skin disorders.

Safety Profile and Side Effects

Calcipotriene is generally considered to have a favorable safety profile, with mild adverse effects occurring in some patients. Common side effects of calcipotriene ointment and cream include:

- Skin irritation, including burning, itching, and redness
- Folliculitis and skin dryness
- Hyperpigmentation or rash
- Increased calcium levels in the blood and urine (hypercalcemia)

More serious adverse effects are rare but include the exacerbation of psoriasis or the development of new skin rashes and dermatitis, which may require cessation of treatment. Given its mechanism of action, calcipotriene does not typically cause significant systemic toxicity. However, its use in combination with ultraviolet (UV) light therapy is cautioned against, as it can increase the risk of skin cancer. Patients are advised to minimize exposure to both natural and artificial sunlight during treatment.

Hypercalcemia is another concern, particularly with prolonged use or overuse of calcipotriene. Regular monitoring of serum calcium levels is recommended during treatment, particularly for patients using high doses or for extended periods.

Regarding pregnancy, calcipotriene should only be used when clearly necessary, as animal studies have shown potential teratogenic effects. However, there are no sufficient studies in pregnant women to determine its safety profile, so it is important for women planning pregnancy to discuss treatment options with their healthcare provider.

Conclusion

Calcipotriene is a synthetic vitamin D analog with proven efficacy in treating psoriasis and several other dermatologic conditions. Its mechanism of action involves the regulation of keratinocyte proliferation and immune system modulation, which provides a therapeutic benefit in managing inflammatory skin diseases. Although the drug has an excellent safety profile, care should be taken to monitor for side effects such as skin irritation and hypercalcemia, and to avoid excessive UV exposure during treatment. With ongoing research into its off-label applications, calcipotriene continues to be a valuable addition to the therapeutic arsenal for managing various cutaneous disorders.

References

- Almeida, L. M., Martins, C., & Cruz, M. T. (2019). Calcipotriol and its applications in dermatologic diseases: A comprehensive review. *Journal of Clinical and Aesthetic Dermatology*, 12(7), 31-38.
- Blauvelt, A., Gottlieb, A. B., & Vender, R. (1996). Vitamin D analogs in the treatment of psoriasis: New opportunities. *Journal of the American Academy of Dermatology*, 34(5), 721-728. https://doi.org/10.1016/S0190-9622(96)70145-X
- Gottlieb, A. B., & Rischard, F. (2004). Topical calcipotriene for psoriasis: A review of its efficacy and safety. *Dermatology Clinics*, 22(3), 323-329. https://doi.org/10.1016/j.det.2004.03.008

- Housman, T. S., Markey, M. E., & Siegel, M. A. (2008). Calcipotriene in the treatment of moderate-to-severe scalp psoriasis. *Journal of the American Academy of Dermatology*, 58(6), 957-963. https://doi.org/10.1016/j.jaad.2007.11.008
- Sbidian, E., Roudot-Thoraval, F., & Rousset, L. (2012). Calcipotriene for the treatment of psoriasis: A systematic review. *Journal of the European Academy of Dermatology and Venereology*, 26(6), 703-711. https://doi.org/10.1111/j.1468-3083.2011.04186.x